博瑞医药(688166) - 2023 Q3 - 季度财报

Financial Performance - Net profit for the third quarter was CNY 176,740,694.87, a slight decrease from CNY 177,878,679.31 in the same period last year[24]. - The company reported a loss of CNY 2,066,517.40 from fair value changes of financial assets and liabilities in the current period[3]. - The net profit attributable to shareholders was CNY 191.79 million, a decrease of 2.95% year-on-year, primarily due to changes in product structure[30]. - The net profit attributable to shareholders for the current reporting period is RMB 82,350,373.20, showing a decrease of 3.82% compared to the same period last year[63]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is RMB 82,732,282.66, down by 4.09% year-on-year[63]. Revenue and Sales - The company’s total revenue for the first three quarters was not explicitly stated but reflects a downward trend in cash received from sales compared to the previous year[26]. - For the first three quarters of 2023, the company achieved operating revenue of CNY 914.88 million, a year-on-year increase of 18.46%[30]. - The sales revenue from product sales reached CNY 775.83 million, up 12.32% compared to the same period last year[33]. - Revenue from raw material drug products was CNY 673.78 million, an increase of 9.71% year-on-year, while formulation product revenue grew by 33.34% to CNY 102.04 million[33]. - Technical income surged by 59.79% to CNY 82.25 million, and revenue from equity sharing increased by 75.04% to CNY 44.98 million[33]. Assets and Liabilities - Total assets increased by 6.53% year-on-year, reaching CNY 4,965,783,541.33 as of the end of the reporting period[14]. - As of September 30, 2023, total assets amounted to CNY 4.97 billion, compared to CNY 4.66 billion at the end of 2022[38]. - The company’s total liabilities and shareholders' equity reached CNY 4.97 billion, reflecting a growth from CNY 4.66 billion in the previous year[38]. - The total liabilities amount to RMB 2,525,042,236.83, an increase from RMB 2,419,587,075.54 in the previous year[70]. Cash Flow - The company reported a cash flow from operating activities of CNY 681,771,316.43 for the first three quarters, down from CNY 824,618,358.29 in the previous year[26]. - The net cash flow from financing activities was CNY 66,683,772.89, significantly lower than CNY 883,781,300.36 in the same period last year[27]. - The net cash flow from operating activities decreased by 51.99% due to an increase in the proportion of received bills and a decrease in tax refunds received compared to the previous year[53]. - Operating cash inflow totaled $768.75 million, a decrease from $922.22 million in the previous period, representing a decline of approximately 16.6%[77]. - Net cash flow from operating activities was $98.83 million, down from $205.84 million, indicating a decrease of about 52%[77]. Research and Development - R&D investment increased by 33.67% in the reporting period, reflecting the company's commitment to a "R&D-driven" strategy[53]. - The total R&D investment for the current period is RMB 60,427,215.89, an increase of 33.67% compared to the same period last year[63]. - R&D investment accounts for 18.46% of operating revenue, an increase of 1.84 percentage points year-on-year[63]. - The company has several major R&D projects in progress, including clinical trials for BGC0228 and BGM0504, with ongoing patient recruitment[68]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 12,818[42]. - The top shareholder, Yuan Jiandong, holds 26.87% of the shares, while the second-largest shareholder holds 6.34%[42]. - The company has a total of 4,523,246 shares held by Huai'an Fund - Huaneng Trust[54]. Construction and Development - The construction progress of the Suzhou inhalation agent and other chemical drug formulation production base is advancing, with various structures completed or nearing completion[8]. - The company is in the process of preparing for the second phase of its Suzhou inhalation and other chemical drug formulation production base, which is currently in the electromechanical installation and debugging stage[35]. - The company has completed construction and commissioning of the BoRui (Shandong) raw material drug phase I project, which is now ready for trial production[46]. - The company is in the trial production phase for its Suzhou high-end formulation drug production project, with various construction milestones nearing completion[69]. Regulatory and Compliance - The company received approval for the listing application of bromfenac raw material drugs in the domestic market during Q3 2023[55]. - The company submitted ANDA for sulodexide injection to the US and CEP for iodinated contrast agent raw materials to Europe in Q3 2023[55]. - The company ensures the accuracy and completeness of the financial information in the quarterly report[62].